Showing posts with label Acute. Show all posts
Showing posts with label Acute. Show all posts

Monday, January 15, 2018

Nuclear War is Much More Likely (Revelation 15)

http://www.thedailysheeple.com/wp-content/uploads/2012/09/nuclear-bomb-explosion2.jpgA new Trump administration plan makes nuclear war likelier
The Trump administration’s wizards of Armageddon have locked down their vision of the nuclear future. It is, by and large, a rehash of old thinking from previous administrations, but its one key departure is a doozy: It declares a newfound readiness to use U.S. nuclear weapons first and early in a confrontation with Russia and possibly others.
Alarmingly, the wizards have uprooted the nuclear taboo and deluded themselves into believing that nuclear weapons are far more usable than previous presidents held. In a single ill-conceived stroke, they have expressed a readiness to go nuclear first in a conflict with Russia or others that had not yet crossed the nuclear Rubicon. This is needless because the United States possesses ample conventional strength to repulse Russian aggression, and reckless because all it accomplishes is increasing the risk of blundering into a nuclear war.
The new Nuclear Posture Review mostly reiterates previous commitments. It defends spending $1.25 trillion to replace aging nuclear forces with new ones, including building new missiles for emplacement in vulnerable silos, and “protecting” them by preparing to launch them on early warning before incoming warheads destroy them. The wizards thus perpetuate the drill that compels presidents to render a launch decision in six minutes or less.
Where the review goes ballistic is its assignment of U.S. nuclear weapons to deter — and if deterrence fails, to attack Russia if Russian President Vladimir Putin orders a non-nuclear strategic attack against the United States and its NATO allies. This mission is alleged to justify acquiring additional weapons with low-yield explosive power (in addition to the 1,000 already operational or held in reserve) to buttress the credibility of this first-use threat.
What is the feared scenario of Russia aggression that would warrant such escalation? The document points to what it calls non-nuclear strategic attacks against civilian populations and infrastructure: “The United States would only consider the use of nuclear weapons in extreme circumstances to defend the vital interests of the United States, its allies, and partners. Extreme circumstances could include significant non-nuclear strategic attacks. Significant non-nuclear strategic attacks include, but are not limited to, attacks on the U.S., allied, or partner civilian population or infrastructure.”
Is this scenario realistic? Possibly. There is strong reason to believe that in wartime the Russians have the capability and the intention to attack U.S. and Western European civilian infrastructure (financial, energy, transportation and communications) with cyber and conventional forces (very possibly including ground-launched cruise missiles with non-nuclear warheads). Russia’s plan envisions surgical strikes against infrastructure during a conventional conflict it is losing in a bid to reverse the fortunes of war.
How? Bizarre as it may seem, the Russians appear to believe that paralyzing or even just severely disrupting “normal life” in the West would so inconvenience the populaces that they would demand their governments end the conflict. Depriving civilians of their iPhones and other amenities is viewed as key to coercing the West to stand down. Of course, some of this disruption — say, electrical blackouts — would cause more than inconvenience; it could mean life or death for thousands.
Russia developed this doctrine over the past five years partially to exploit growing infrastructure vulnerabilities stemming from growing Western dependencies on these networks, and partially to reduce Russia’s own strategic reliance on first use of nuclear arms. By focusing on cyberwar and conventional forces, Russia seeks to depend less on its 20-year-old doctrine of “escalate to de-escalate,” which calls for the early first use of small-yield Russian tactical nuclear weapons to counter Western conventional supremacy. (This Russian option is also cited by the Trump review as a reason for acquiring and using countervailing low-yield U.S. nuclear weapons.)
The West’s Achilles’ heel of infrastructure vulnerability may tempt other adversaries besides Russia to take aim at this weakness in wartime. Indeed, the Trump administration’s document leaves the door ajar for possible U.S. nuclear first strikes against non-nuclear countries if they wreck our critical civilian infrastructure.
But for the U.S. to react to growing threats to civilian networks by proposing to use new low-yield U.S. nuclear weapons is particularly ill-conceived. The administration’s new doctrine reverses roles and puts the onus on the United States to be the first to initiate the use of nuclear weapons. Russia has managed to turn the tables on us, increasing U.S. reliance on early first use. The Pentagon has fallen into a trap by boxing itself in this way and almost casually lets Russia off the hook.
The burden of nuclear first use should remain on Russia and not be allowed to shift onto NATO. No American president wants to feel pressure to authorize the early first use of nuclear weapons. The correct approach is for the West to exploit its own cyber and conventional prowess to counter Russia on its own terms, exploiting Western superiority in these areas and leaving the burden of nuclear first use on Russia’s shoulders. We need tighter, not looser rules for using nukes first in a confrontation with Russia. President Trump should expunge this major new creative, but misguided, part of his nuclear review — and fire its authors.

Wednesday, March 22, 2017

Sweden Prepares For Nuclear War (Revelation 15)

Sweden preparing nuclear fallout bunkers across the country amid fear of Russian war

War preparations come as Nordic country reintroduces military conscription
NUCLEAR war shelters are being readied in Sweden to prepare for a surprise Russian attack, according to reports.
The Swedish Civil Contingencies Agency (MSB) has reportedly been ordered to carry out a review this year of bunkers the coming weeks as the Scandinavian country also reintroduces military service.
Bunkers are being reviewed in Sweden in case war breaks out with Russia
Bunkers are being reviewed in Sweden in case war breaks out with Russia to protect as many as seven million people
A system of 65,000 bunkers was established in the Cold War to protect the population from nuclear war with the Soviet Union.
According to MSB, the bunkers currently protect against blast and radiation as well as chemical or germ warfare.
With a distinctive logo, they can easily be located by civilians seeking shelter.
But with fears growing over threat posed by Vladimir Putin and his resurgent Russia they are being reviewed to make sure they are ready.
Russian military drills in the region have raised fears among neighbouring nations that an attack could happen in the coming months.
Civil defence measures are therefore being stepped up, especially in the Island of Gotland where Sweden has already re-opened a garrison.
Swedish broadcaster Sveriges Radio reported that Mats Berglund had ordered a review of the island’s 350 civilian bunkers.
Should you be in Sweden and need to take shelter this is a public nuclear bunker sign
Should you be in Sweden and need to take shelter this is a public nuclear bunker sign
The network of public bunkers originates from the Cold War but are now being dusted down, according to reports
The network of public bunkers originates from the Cold War but are now being dusted down, according to reports

Thursday, March 16, 2017

Preparing For The Nuclear War (Revelation 15)

AUTHOR: MEGAN MOLTENI. MEGAN MOLTENI SCIENCE DATE OF PUBLICATION: 03.14.17
Last week, as tens of thousands of US and South Korean soldiers gathered at a base in Iwakuni, Japan for an annual joint military exercise, North Korea fired four ballistic missiles from Pyongyang into the sea off Japan’s northwest coast. In a world where the US is headed by a Twigger-happy political neophyte and the risk of a Cold War reboot looms larger with each Wikileaks disclosure, this demonstration wasn’t just an empty display of dictatorial propaganda. It was a reminder that the nuclear threat is still alive and well.
But even if you’ve taken a decades-long break from stocking your fallout shelter, the federal government hasn’t. Over the last ten years the US has poured millions of dollars into technologies and treatments it hopes to never have to use, but could, in the event of a nuclear catastrophe. From assays that measure radiation exposure to cell therapies that restore dwindling blood cells to liquid spray skin grafts, government officials are now far better equipped to deal with diagnosing and treating people if the unthinkable were to happen. And the next generation of treatments are being funded right now.
In 2006, the Department of Health and Human Services established the Public Health Emergency Medical Countermeasures Enterprise to coordinate federal solutions to large-scale public health threats, including the nuclear one. Pretty much every agency you can think of is involved—CDC, NIH, FDA, DoD, DHS, USDA, VA, and OEM, among others. But in terms of nuclear countermeasures, three programs nested within HHS do the bulk of the heavy lifting.
The NIH’s National Institute of Allergy and Infectious Disease is the first stop; it runs clinical and preclinical trials for promising technologies. Then there’s the Biomedical Advanced Research and Development Authority—Barda—which is basically a taxpayer-backed investment firm that develops these potential drugs, vaccines, treatments, and supplies and ushers them through FDA approval. Finally there’s Project BioShield, which Barda uses to contract with companies when their products are almost ready, ensuring a national market. To date, the program has acquired 12 products related to a nuclear blast or reactor meltdown, some FDA-approved, some still in late stage development, but all destined for the Strategic National Stockpile, the CDC-managed backup supply of drugs and medical supplies for use in a public health emergency. And each class of products addresses a different part of the threat.
The first is diagnosis. When a person is exposed to high levels of radiation, unpaired electrons careen around their cellular machinery, breaking DNA and causing damage to every organ, including the bone marrow. This means you can’t generate new red blood cells, white blood cells, and platelets, so you can’t fight off infections or coagulate your blood. People usually don’t start feeling the effects of acute radiation syndrome for 24 to 48 hours, but damage to their cells’ DNA starts almost immediately. Which is why you need a reliable diagnostic device; following a nuclear event, people who feel well might actually be in danger, and people who weren’t exposed will want treatment just to be safe.
So using Project BioShield, Barda has acquired two diagnostic devices, known as biodosimeters, to tell the difference. One works by measuring gene expression, the other by visually analyzing cell nuclei. “In the event of a nuclear event, the countermeasures we’ve procured will be precious resources,” says Joe Larsen, acting director of Barda’s division of chemical, biological, radiological, and nuclear medical countermeasures. “We’re going to end up with a lot of worried well demanding treatment, and we can only afford to treat people that need it.”
That treatment, at least right now, consists of injections of immune-boosting cytokines, developed for cancer patients to restore depleted white blood cells lost during radiation treatments or chemotherapy. Project BioShield has acquired three such cytokine treatments—but, Larsen notes, they won’t work for about 20 percent of people. For them, the only option will be bone marrow or cord blood transplants, which come with the extra obstacle of having to be matched with a donor. So Barda is now looking for cellular therapies that don’t require any donor matching to their portfolio—a universal treatment. “That could shore up gaps in our initial capability to treat radiation.” And they’ve got at a few promising options coming down the pipeline.
Barda recently signed a $188 million contract to develop a stem cell therapy produced by California-based Cellerant Therapeutics, which restores white blood cells in leukemia patients who’ve had theirs taken out by chemotherapy. The cells are cryopreserved and shelf-stable, important features for a stockpile item. But the treatment is focused on white blood cells, and radiation exposure doesn’t limit itself to the immune system’s front-line fighters.
To that end, NIAID is funding clinical trials for a placenta-derived stem cell treatment developed by an Israeli company, Pluristem, that has shown the ability to restore all three blood cell lines—red and white blood cells, as well as platelets—in animal models. Like Cellerant’s, the treatment comes cryogenically frozen along with a thawing device to deploy it easily in the field. The cells stay viable on liquid nitrogen inside their canisters, so you don’t have to worry about losing them if the power goes out. From their injection site, the placental stem cells sense stress signals in bone marrow tissues, and send more than 20 signaling molecules to repair and restore their functions. The company isn’t testing efficacy in humans, for obvious reasons. But Pluristem says their animal studies showed close to 100 percent survival rates with the treatment, compared to 30 percent without.
Arik Eisenkraft, who began working on an ARS application for Pluristem’s technology following the Fukushima disaster, isn’t surprised that a potential solution to nuclear radiation would come out of a place like Israel. “We live in a world of imminent threats, not theoretical ones,” he said. “Even though we don’t have the same budgets and the same scope of institutes, what we do have is a real sense of urgency.”
Neither Barda nor Pluristem could confirm whether or not a contract is somewhere in their future. But the agency did say it was looking at all the options. And with Barda’s budget cut by $160 million last year and an uncertain future for disaster preparedness funds in a Trump administration, there’s no time like the present for some urgency of their own.